New Hope for Alzheimer’s: Blocking a Single Protein Restores Brain Immune Function
Cold Spring Harbor Laboratory researchers have identified a promising new strategy for treating Alzheimer’s disease by targeting a protein that hinders the brain’s natural cleanup crew.
“Our results suggest that PTP1B inhibition can improve microglial function, clearing up Aβ plaques.”
— Yuxin Cen, Graduate Student
The Discovery
Led by Professor Nicholas Tonks, the research team found that blocking the protein PTP1B significantly improves learning and memory in a mouse model of Alzheimer's disease.
PTP1B interacts with spleen tyrosine kinase (SYK), a critical regulator of microglia—the brain's immune cells responsible for clearing harmful amyloid-β (Aβ) plaques. In Alzheimer's disease, these microglia become progressively exhausted and ineffective.
A Dual-Action Approach
Unlike current Alzheimer's therapies, which focus solely on reducing amyloid-β buildup and offer limited benefits for many patients, PTP1B inhibition may address the underlying immune dysfunction:
- Restores microglial function, enabling them to clear plaques more effectively
- Reduces plaque buildup, tackling the disease at its source
“Over the course of the disease, these cells become exhausted and less effective.”
— Yuxin Cen
The Broader Context
Discovered by Tonks in 1988, PTP1B is already a well-established target for metabolic disorders like obesity and type 2 diabetes—both significant risk factors for Alzheimer’s disease. This dual relevance makes the protein an especially compelling therapeutic target.
Future Directions
The Tonks lab is collaborating with DepYmed, Inc. to develop PTP1B inhibitors for multiple medical applications.
“Using PTP1B inhibitors that target multiple aspects of the pathology, including Aβ clearance, might provide an additional impact.”
— Steven Ribeiro Alves, Postdoctoral Fellow
Researchers are also exploring the potential combination of PTP1B inhibitors with existing approved Alzheimer’s drugs, which could create a more comprehensive treatment regimen.
“The goal is to slow Alzheimer's progression and improve quality of life of the patients.”
— Nicholas Tonks, Professor